Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries

Journal of Viral Hepatitis

Volumn 21, Issue 9, 2014, Pages 662-670

  Leblebicioglu, H ^a   Arama, V ^b   Causse, X ^c   Marcellin, P ^d   Ozaras, R ^e   Postawa Klozinska, B ^f   Simon, K ^g   Suceveanu, A I ^h   Wiese, M ⁱ   Zeuzem, S ^j   Klauck, I ^k   Morais, E ^k   Bjork, S ^l   Lescrauwaet, B ^m   Kamar, D ⁿ   Zarski, J P ^o  

^a ONDOKUZ MAYIS UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^d BEAUJON HOSPITAL   (France)

^e ISTANBUL UNIVERSITY   (Turkey)

^f Specjalist Szpital Zeromskiego   (Poland)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h Spitalul Clinic Jude ean de Urgen Constan a   (Romania)

ⁱ Klinikum St Georg   (Germany)

^j UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^k BRISTOL MYERS SQUIBB   (United States)

^l Institute of Applied Economics and Health Research   (Denmark)

^m Xintera Consulting Bvba   (Belgium)

ⁿ DOCS International   (France)

^o GRENOBLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

adefovir; antiviral treatment; chronic hepatitis B; entecavir; lamivudine; tenofovir

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRANCE; GERMANY; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POLAND; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; ROMANIA; TREATMENT INITIATION; TREATMENT OUTCOME; TREATMENT PLANNING; TURKEY (REPUBLIC); VIRUS LOAD; ADOLESCENT; AGED; BLOOD; EUROPE; GEOGRAPHY; HEPATITIS B, CHRONIC; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; EUROPE; FEMALE; GEOGRAPHY; HEPATITIS B, CHRONIC; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VIRAL LOAD; YOUNG ADULT;

EID: 84905510084     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12202     Document Type: Article

References (10)

1. Ott JJ, Stevens GA, Groeger J, Wiersma J,. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219.
2. Hatzakis A, Wait S, Bruix J, et al,. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18 (Suppl 1): 1-16.
3. Yim HJ, Lok AS,. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-S181.
4. McMahon BJ,. The natural history of chronic hepatitis B virus infec-vtion. Hepatology 2009; 49: S45-S55.
5. Chen CF, Lee WC, Yang HI, et al,. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011; 141: 1240-1248.
6. Chen CJ, Yang HI,. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26: 628-638.
7. Liaw YF, Kao JH, Piratvisuth T, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hep Intl 2012; 6: 531-561.
8. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
9. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
10. Marcellin P, Arama V, Leblebicioglu H, et al,. Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study. Antivir Ther 2013. Doi: 10.3851/IMP2573.